Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD.
E G B VijverbergT M AxelsenA R BihletK HenriksenF WeberK FuchsJ E HarrisonK Kühn-WacheP AlexandersenN D PrinsPhilip ScheltensPublished in: Alzheimer's research & therapy (2021)
ClinicalTrials.gov Identifier: NCT04498650.